Associate Professor @PennMedicine | @PennMicro | CAR T cells, immunotherapy, epigenetics, T cell exhaustion, synthetic biology, correlative sciences
Philadelphia, PA
Joined December 2023
- Tweets81
- Following237
- Followers352
- Likes84
October shopping that supports cancer research! CARO Home is donating 15% of sales of pink items this month to Swim Across America, helping fund our ovarian cancer research. Thank you for helping turn promising ideas into progress for patients! instagram.com/p/DeSgVUTRxUI/
Joseph Fraietta retweeted
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
@seattlechildren @TexasChildrens @NIH
Joseph Fraietta retweeted
.@PennCancer's David Porter, MD, joined @TIME's panel on expanding access to lifesaving care, offering insights on making CAR T cell therapy more widely available.
On September 10, TIME hosted the third annual TIME100 Health Leadership Forum in New York City. Here's what health leaders said about expanding access to specialty care: time.com/collection/time100-…
Joseph Fraietta retweeted
A video shows a patient with progressive multiple sclerosis attempting to walk before and after treatment with JY231, an off-the-shelf lentiviral vector designed for the direct in vivo engineering of CD19-targeted CAR T cells. Learn more in the preliminary results of a phase 1 trial: nej.md/4zPPwbD
Joseph Fraietta retweeted
At @PennMedicine, we see the extraordinary in bold breakthroughs and in small kindnesses. This Labor Day, we celebrate every one of our faculty and staff. Watch what their collective care made possible for Nydia and Kim. spr.ly/6009B1C0jX
Joseph Fraietta retweeted
I’m amazed at how much better the results of CART are in CLL in the real world than on trials. So many MRD-negative CRs. First we clear the lymphocytes before apheresis, then bring the residual disease as low as possible before CAR T, then continue the BTKi through CAR T.
Huge congratulations to Janna Minehart MD on receiving the SITC-Merck Cancer Immunotherapy Clinical Fellowship! Her project, “Improving CAR T-cell function with a reversible TET2 ‘off switch,’” will explore a really exciting strategy to reprogram CAR T cells for improved function
One of my first non-CAR T papers in a while!
This one started as an idea I had in the shower years ago, and the extremely talented Ángel Ramírez-Fernández somehow turned that highly rigorous scientific origin story into an actual paper.
link.springer.com/article/10…
Thrilled to see our new paper out in Blood! We identify T-cell immunosenescence as a major barrier to CD19 CAR T-cell function in CLL and show that this dysfunctional state may be therapeutically modifiable.
Huge congratulations to Julia Han Noll! 🎉
ashpublications.org/blood/ar…
Joseph Fraietta retweeted
The cohosts spoke with Kristopher R. Bosse, MD, (@ChildrensPhila) about how #immunotherapy is reshaping treatment for high-risk #neuroblastoma.
#ImmunoLogic #oncology
@JoeFraietta @PennMedicine
Watch:
hubs.li/Q049CPBs0
Joseph Fraietta retweeted
Leveraging #ComputationalBiology at scale to individualize #Immunotherapy: nature.com/articles/s41551-0… @JoeFraietta @carlhjune #CARTcelltherapy #CellTherapy #CARTCell #TranslationalScience
Joseph Fraietta retweeted
The cohosts spoke with Julia C. Tchou, MD, PhD (@tchou_julia, @pennsurgery) about the potential of combining #immunotherapy approaches and #surgery in the treatment of #breastcancer
#ImmunoLogic #oncology @PennMedicine @JoeFraietta
Watch:
hubs.li/Q042FZWP0
Joseph Fraietta retweeted
In this bonus episode of #ImmunoLogic, the hosts discussed #Immunotherapy highlights from #ASH25 (@ASH_hematology)
#Oncology @PennMedicine @JoeFraietta
Watch now:
hubs.li/Q03ZkBHw0
Joseph Fraietta retweeted
ICYMI:
#ImmunoLogic cohosts Janna Minehart, MD, and Joseph Fraietta, PhD, shared their thoughts on major @US_FDA actions in 2025.
#immnunotherapy #oncology
Joseph Fraietta retweeted
#ImmunoLogic cohosts Janna Minehart, MD, and Joseph Fraietta, PhD, on the potential of #TumorInfiltratingLymphocyte expansion and new in vivo #CART data in 2026.
#immnunotherapy #oncology
Joseph Fraietta retweeted
#ImmunoLogic cohosts Janna Minehart, MD, and Joseph Fraietta, PhD, shared their thoughts on major @US_FDA actions in 2025.
#immnunotherapy #oncology
Joseph Fraietta retweeted
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events (CN palsies, parkinsonism, colitis) after ide- or cilta-cel, and are associated with higher NRM #mms #bmtsm @MatthewHoMD @jh_noll @JoeFraietta @PennMedicine nature.com/articles/s41591-0…
Happy to announce publication of our new paper: CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy | Nature Biomedical Engineering Congratulations, Angel and Team!!! nature.com/articles/s41551-0…
Joseph Fraietta retweeted
Catch Dr. Catherine Wu’s keynote on Therapeutic cancer vaccines at #ESMO25 on Oct 19! Proud to see PICI and Dana-Farber researchers sharing major findings in breast, lung and bladder cancers. Learn more about DFCI’s work here: bit.ly/4hhWXQ6